KalVista Pharmaceuticals Newsroom

KalVista Pharmaceuticals to Present at the Citizens Life Sciences Conference

KalVista PharmaceuticalsApr 30 00:00 ET

BofA Securities Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $22

Moomoo NewsApr 15 06:31 ET · Ratings

Major Investment Alert: KalVista Pharmaceuticals Sees Significant Stock Purchase!

TipRanksApr 11 22:02 ET

Needham Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $28

Moomoo NewsApr 9 02:31 ET · Ratings

JMP Securities Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $19

Moomoo NewsApr 9 02:31 ET · Ratings

JonesTrading Maintains KalVista Pharmaceuticals(KALV.US) With Buy Rating, Maintains Target Price $30

Moomoo NewsApr 9 02:31 ET · Ratings

Express News | Needham Reiterates Buy on KalVista Pharma, Maintains $28 Price Target

BenzingaApr 8 08:16 ET

KalVista Signs Deal With Kaken to Commercialize Hereditary Angioedema Treatment in Japan

MT NewswiresApr 8 07:41 ET

Analysts Offer Insights on Healthcare Companies: KalVista Pharmaceuticals (KALV), Humana (HUM) and PROCEPT BioRobotics (PRCT)

TipRanksApr 8 06:40 ET · Ratings

Express News | Kalvista Pharmaceuticals Inc - up to $24 Mln in Upfront and Milestone Payments, Plus Royalties

ReutersApr 8 06:30 ET

Express News | Kalvista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for Hae in Japan

ReutersApr 8 06:30 ET

KalVista Pharmaceuticals Enters Into Licensing Agreement With Kaken Pharmaceutical to Commercialize Sebetralstat for HAE in Japan

KalVista PharmaceuticalsApr 8 00:00 ET

Will KalVista Pharmaceuticals (NASDAQ:KALV) Spend Its Cash Wisely?

Simply Wall StApr 2 08:42 ET

KalVista Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

KalVista PharmaceuticalsApr 2 00:00 ET

KalVista Pharmaceuticals to Present at 24th Annual Needham Virtual Healthcare Conference

KalVista PharmaceuticalsMar 31 00:00 ET

A Quick Look at Today's Ratings for KalVista Pharmaceuticals(KALV.US), With a Forecast Between $28 to $39

Moomoo NewsMar 27 09:00 ET · Ratings

KalVista Pharmaceuticals' Strategic Readiness and Market Potential Drive Buy Rating for Sebetralstat

TipRanksMar 27 07:25 ET · Ratings

Analysts' Opinions Are Mixed on These Healthcare Stocks: Theratechnologies (THTX), KalVista Pharmaceuticals (KALV) and Mereo Biopharma Group Plc (MREO)

TipRanksMar 26 09:20 ET · Ratings

KalVista Pharmaceuticals Price Target Maintained With a $30.00/Share by Jones Trading

Dow JonesMar 26 09:09 ET · Ratings

KalVista Pharmaceuticals Is Maintained at Buy by Jones Trading

Dow JonesMar 26 09:09 ET · Ratings